Overview

Bioinformation Therapy for Lung Cancer

Status:
Completed
Trial end date:
2018-09-02
Target enrollment:
0
Participant gender:
All
Summary
The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable lung cancer.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Fuda Cancer Hospital, Guangzhou
Collaborator:
Shengxin Biotechnology Institute, Beijing
Treatments:
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- All standard therapies have failed according to NCCN guidelines or the patient refuses
standard therapies

- Body tumor 1-6, with at least one tumor length > 2 cm

- KPS ≥ 70, lifespan > 6 months

- Platelet count ≥ 80×109/L,white blood cell count ≥ 3×109/L, neutrophil count ≥
2×109/L, hemoglobin ≥ 80 g/L

Exclusion Criteria:

- Patients with cardiac pacemaker

- Patients with brain metastasis

- Patients with grade 3 hypertension or diabetic complication, severe cardiac and
pulmonary dysfunction